PRESS: Inside huge top-secret legal cannabis facility hidden away in Birmingham that is the size of three football pitches
Celadon has been published in the Birmingham Mail on 30th July 2022.
Celadon, a leading medical cannabis lab in the UK, has recently begun its first clinical trial for a product designed to treat illnesses such as epilepsy and chronic pain disorders. Our state-of-the-art facility is tightly under wraps to ensure patient privacy and safety. Our product has been a revelation, with CEO James Short stating that it has helped his sister, who suffers from MS, go from being on a tablet for 20 years to taking none.
We understand that cannabis has had a negative stigma in the past, but we believe that our product is an alternative that the world needs. It is a safe and effective option for patients suffering from chronic pain, and it is our mission to make it accessible to as many people as possible.
Click here to read the full story.
OTHER POSTS
-
PRESS: Britain could be getting high on the benefits of a full-scale medical cannabis industry
-
PRESS: British Pain Society features Celadon Pharmaceuticals Plc
-
PRESS: Celadon Pharmaceutical’s CEO Jim Short featured discussing new MHRA framework
-
BUSINESS UPDATE: Celadon Pharmaceuticals Plc (CEL) Announces Interim Results